Use of low-dose topiramate in substance use disorder and bodyweight control

Yi Hang Chiu, Ting Hui Lee, Winston W. Shen

研究成果: 雜誌貢獻文章同行評審

9 引文 斯高帕斯(Scopus)


In recent years topiramate has been used for psychiatric patients, mainly for controlling substance use and food intake. A total of 46 patients who received topiramate treatment during the study period were identified from a computer database. Nineteen had received topiramate for at least 1 month. Twelve patients received topiramate for anticraving effects (alcohol, n = 9; heroin/amphetamine, n = 1; meperidine, n = 1; and nicotine, n = 1). On an average dosage of 112.5 mg/day, nine of the 12 patients (excluding three alcoholic patients) achieved complete or partial remission from the substance use disorders. The present results show that six of the nine patients achieved full or partial remission from alcohol use disorder on a dosage of 100 mg/day. Topiramate was also used to control seven patients' bodyweight (mean bodyweight change, 1.53 kg). Four of them achieved bodyweight loss in the 1-month follow up, with an average change of 2.65 kg. Based on the present findings topiramate
頁(從 - 到)630-633
期刊Psychiatry and Clinical Neurosciences
出版狀態已發佈 - 12月 2007

ASJC Scopus subject areas

  • 神經病學(臨床)
  • 神經內科
  • 精神病學和心理健康
  • 神經科學 (全部)


深入研究「Use of low-dose topiramate in substance use disorder and bodyweight control」主題。共同形成了獨特的指紋。